Multiple SclerosisABIF-MSNCT07640100
EFFECTS OF AEROBIC AND RESISTANCE TRAINING ON IMMUNE FUNCTION IN MULTIPLE SCLEROSIS
A study testing Aerobic and Progressive Resistance Exercise Program in people with Multiple Sclerosis, run by Seda Saka at 1 site in Turkey (Türkiye).
Trial summary
Background: Multiple Sclerosis (MS) is a chronic immune-mediated, inflammatory, and neurodegenerative central nervous system disorder characterized by axonal damage. This damage leads to various debilitating symptoms such as muscle weakness, fatigue, balance loss, and cognitive decline. Read more about this study
- Who is it for?
- Ages 19 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- Aerobic and Progressive Resistance Exercise Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2026to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS). Aged between 19 and 45 years. Expanded Disability Status Scale (EDSS) score between 0.5 and 3.5. Not currently receiving steroid therapy (or having no recent corticosteroid treatment within the specified washout period).
Who cannot join
- Having a high baseline level of physical activity.
- Experiencing an acute MS relapse or having a history of a relapse within the past 3 months.
- Presence of any orthopedic or bone pathology that would prevent participation in the exercise program.
- Concomitant diagnosis of any known neuromuscular or immunological disease other than MS.
- Initiating immunomodulatory therapy within the last 6 months.
- Presence of visual involvement or symptomatic diplopia.
Show all 9Show fewer
- High-grade lower extremity spasticity, defined as a Modified Ashworth Scale (MAS) score of 3 or 4.
- Abnormal white blood cell (WBC) count outside the normal reference range of 4,000-10,000 cells/µL.
- Presence of any severe cardiopulmonary condition that would contraindicate or prevent participation in physical exercise.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Van Regional Training and Research Hospital
Van, Ipekyolu, 65100
VAN REGIONAL TRAINING AND RESEARCH HOSPITAL REGIONAL TRAINING AND RESEARCH HOSPITAL, +905555798488, dr_m_okay@hotmail.com
muhammed örün, specialist, +905555798488, dr_m_okay@hotmail.com
About this study
Official title: EVALUATION OF THE EFFECTS OF AEROBIC AND RESISTANCE EXERCISES ON THE IMMUNE SYSTEM AND FUNCTIONAL CAPACITY IN MULTIPLE SCLEROSIS
Background: Multiple Sclerosis (MS) is a chronic immune-mediated, inflammatory, and neurodegenerative central nervous system disorder characterized by axonal damage. This damage leads to various debilitating symptoms such as muscle weakness, fatigue, balance loss, and cognitive decline. While reductions in aerobic capacity and muscle strength are secondary manifestations of MS, physical exercise serves as a crucial therapeutic strategy to manage symptoms and optimize functionality.
Rationale: Aerobic exercise exerts anti-inflammatory effects by reducing adipose tissue mass, promoting anti-inflammatory macrophage polarization, and downregulating toll-like receptors. It also modulates the altered T-helper cytokine balance in MS (characterized by elevated proinflammatory cytokines like IL-1, IL-6, IL-17, IFN-γ, TNF-α and decreased anti-inflammatory IL-10), potentially slowing myelin destruction. Concurrently, progressive resistance training (typically at 60%-80% of maximum voluntary contraction) has been shown to improve muscle strength and reduce perceived fatigue in this population. However, data regarding the specific impacts of these exercise modalities on the immune system remain limited.
Objective:The aim of this randomized controlled trial is to investigate and compare the effects of AEROBIC AND STRENGTHENING (RESISTANCE) EXERCISES ON THE IMMUNE SYSTEM PARAMETERS (SPECIFICALLY CYTOKINE PROFILES) AND OVERALL FUNCTIONALITY IN INDIVIDUALS DIAGNOSED WITH MULTIPLE SCLEROSIS.
Read the detailed description
Multiple Sclerosis (MS) is recognized as a chronic immune-mediated, inflammatory, and neurodegenerative disorder of the central nervous system (CNS) characterized by axonal damage that disrupts neural conduction. The neurodegenerative nature of this neurological disease manifests through a wide spectrum of debilitating symptoms, including muscle weakness, fatigue, loss of balance, speech impairment, diplopia, and cognitive decline. These neurological signs and symptoms vary depending on the anatomical location of the lesions.
As an effective rehabilitation strategy for individuals with MS, exercise manages symptoms, restores function, optimizes quality of life, promotes wellness, and encourages participation in activities of daily living. Previous studies have demonstrated that aerobic activity is inversely associated with MS symptoms, exerting protective and potentially restorative effects. Furthermore, growing evidence suggests that exercise can be considered a disease-modifying therapy in MS. Although reductions in aerobic capacity and endurance are not primary clinical features of MS, they frequently develop as secondary manifestations. Therefore, strategies designed to enhance aerobic endurance and capacity, such as aerobic exercise, are highly valuable in MS management. Consequently, aerobic-based exercise interventions are frequently utilized in the therapeutic management of MS to improve aerobic endurance and capacity. Aerobik exercise is a modality designed to stress the cardiovascular system through continuous, rhythmic engagement of large muscle groups (e.g., jogging, walking, swimming, rowing, and cycle ergometry).
The anti-inflammatory effect of aerobic exercise may prevent systemic inflammatory progression. Exercise counteracts inflammation by reducing adipose tissue mass, which promotes the polarization of macrophages toward an anti-inflammatory state, thereby limiting cytokine production. Additionally, the downregulation of toll-like receptors associated with decreased inflammatory monocytes occurs. The inflammatory state is also modulated in response to exercise stimulation by increased levels of skeletal muscle-derived interleukin-6 (IL-6) and the prevention of sustained cytokine release associated with obesity. Cytokines, critical components of MS pathophysiology, are protein hormones that regulate communication between the innate and adaptive branches of the immune system. In healthy populations, a homeostatic balance exists among T-helper cytokines; however, this balance is altered in MS, reflecting increased proinflammatory cytokines (IL-1, IL-6) and decreased anti-inflammatory cytokines (IL-10). These aberrations can accelerate myelin destruction in the brain and spinal cord. Data regarding the effects of physical activity on the immune system in MS remain limited. Cytokines, the primary focus of exercise-based MS studies, encompass a spectrum of proinflammatory cytokines, including IL-1, IL-2, IL-6, IL-17, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α). Most of these cytokines are well-documented contributors to MS pathogenesis.
Recently, there has been a growing interest in resistance exercise training. Resistance training studies in individuals with MS have reported improvements in leg strength, reductions in perceived fatigue, and increases in muscle power. Resistance training protocols in this population have generally been of low-to-moderate intensity, typically utilizing progressive resistance exercise ranging from 60% to 80% of the maximum voluntary contraction.
The aim of this study is to conduct a randomized controlled trial to investigate the EFFECTS OF AEROBIC AND STRENGTHENING EXERCISES ON THE IMMUNE SYSTEM AND FUNCTIONALITY IN INDIVIDUALS DIAGNOSED WITH MULTIPLE SCLEROSIS.
- Conditions
- Multiple Sclerosis
- Being tested
- Aerobic and Progressive Resistance Exercise Program, Standard Care (in control arm)
- Keywords
- Multiple Sclerosis, Physical Functional Performance, Cytokines, Immune System
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aerobic and Progressive Resistance Exercise ProgramBehavioural
A structured, supervised exercise program consisting of both aerobic and progressive strengthening (resistance) exercises. Aerobic exercises will include continuous, rhythmic activities involving large muscle groups (e.g., cycle ergometry, walking). Progressive resistance training will target major muscle groups, typically utilizing an intensity ranging from 60% to 80% of the maximum voluntary contraction (MVC). The duration, frequency, and total weeks of the program will be identical for both exercise arms.
Standard Care (in control arm)Other
Participants in this arm will maintain their current routine medical follow-ups and standard daily life activities. They will not participate in any structured or supervised physical exercise program during the study period.
| Study group | Role | What they receive |
|---|---|---|
| MS Exercise group | Experimental | Participants diagnosed with Multiple Sclerosis who will perform a structured exercise program consisting of both aerobic training and progressive strengthening (resistance) exercises. Receives: Behavioral: Aerobic and Progressive Resistance Exercise Program |
| MS Control Group | Active comparator | Participants diagnosed with Multiple Sclerosis who will maintain their current routine medical care and daily life activities without participating in any structured exercise intervention during the study period. Receives: Other: Standard Care (in control arm) |
| healthy Control Group | Experimental | Age- and gender-matched healthy individuals who will perform the identical structured exercise program (consisting of aerobic and progressive strengthening exercises) as the MS Exercise Group. This arm will serve to compare the physiological, functional, and immunological (cytokine profiles) responses to exercise between healthy individuals and individuals with MS. Receives: Behavioral: Aerobic and Progressive Resistance Exercise Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
CHANGE FROM BASELINE IN SERUM PROINFLAMMATORY CYTOKINE LEVELS
Circulating serum levels of proinflammatory cytokines-specifically Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-17 (IL-17), Interferon-gamma (IFN-γ), and Tumor Necrosis Factor-alpha (TNF-α)-will be analyzed via Enzyme-Linked Immunosorbent Assay (ELISA) to evaluate the anti-inflammatory effect of the exercise program.
Measured: Baseline and Post-intervention (e.g., Week 8)
Secondary outcomes (5)
CHANGE FROM BASELINE IN FUNCTIONAL EXERCISE CAPACITY
Evaluated using the 6-Minute Walk Test (6MWT). The total distance walked in meters within 6 minutes will be recorded to assess functional exercise capacity and aerobic endurance.
Measured: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN TIMED 25-FOOT WALK (T25FW)
A MEASURE OF QUANTITATIVE MOBILITY AND LEG FUNCTION BASED ON THE TIME REQUIRED TO WALK 25 FEET AS QUICKLY AS POSSIBLE.
Measured: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN PERCEIVED FATIGUE IMPACT
Assessed using the Modified Fatigue Impact Scale (MFIS). This 21-item self-report questionnaire evaluates the perceived impact of fatigue on physical, cognitive, and psychosocial functioning. Total scores range from 0 to 84, with higher scores indicating a greater negative impact of fatigue.
Measured: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN 9-HOLE PEG TEST (9HPT)
A MEASURE OF UPPER EXTREMITY (ARM AND HAND) FUNCTION BASED ON THE TIME REQUIRED TO PLACE AND REMOVE 9 PEGS IN A PEG BOARD.
Measured: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN PACED AUDITORY SERIAL ADDITION TEST (PASAT-3)
A MEASURE OF COGNITIVE FUNCTION, AUDITORY INFORMATION PROCESSING SPEED, AND CALCULATION ABILITY.
Measured: Baseline and Post-intervention (e.g., Week 8)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a 3-arm, prospective, randomized controlled trial utilizing a parallel assignment design. Participants will be allocated into three distinct groups: MS Exercise Group (Experimental Arm): Individuals diagnosed with MS who will undergo a structured aerobic and strengthening exercise program. MS Control Group (Active/No Intervention Arm): Individuals diagnosed with MS who will maintain their routine medical care without participating in the exercise intervention. Healthy Control Group (Comparison Arm): Age- and gender-matched healthy individuals who will serve as a baseline reference for immune system parameters and functional capacity. The clinical, functional, and immunological outcomes (cytokine profiles) of all groups will be evaluated simultaneously at baseline and post-intervention to compare the treatment effects and baseline differences.
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seda Saka
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Seda Saka, Halic University
- Investigators
- seda saka, Assoc. Prof. Dr., Principal investigator, Haliç University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07640100
- Sponsor's protocol ID
- KAD-FR-42
- Acronym
- ABIF-MS
- Status last verified
- Jun 2026
- First submitted
- 2 Jun 2026
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) collected during this trial will not be shared publicly to ensure patient confidentiality and comply with local data protection laws (Personal Data Protection Law / KVKK) and the institutional ethics committee approval. The ethical approval and informed consent forms signed by the participants do not cover the public repository sharing of raw individual data. However, the aggregated summary results and statistical findings will be made available through peer-reviewed publications.
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EVALUATION OF THE EFFECTS OF AEROBIC AND RESISTANCE EXERCISES ON THE IMMUNE SYSTEM AND FUNCTIONAL CAPACITY IN MULTIPLE SCLEROSIS
- ClinicalTrials.gov ID
- NCT07640100
- Acronym / sponsor ID
- ABIF-MS / KAD-FR-42
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, Physical Functional Performance, Cytokines, Immune System
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Seda SakaUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 10 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Multiple Sclerosis (MS) is a chronic immune-mediated, inflammatory, and neurodegenerative central nervous system disorder characterized by axonal damage. This damage leads to various debilitating symptoms such as muscle weakness, fatigue, balance loss, and cognitive decline. While reductions in aerobic capacity and muscle strength are secondary manifestations of MS, physical exercise serves as a crucial therapeutic strategy to manage symptoms and optimize functionality.
Rationale: Aerobic exercise exerts anti-inflammatory effects by reducing adipose tissue mass, promoting anti-inflammatory macrophage polarization, and downregulating toll-like receptors. It also modulates the altered T-helper cytokine balance in MS (characterized by elevated proinflammatory cytokines like IL-1, IL-6, IL-17, IFN-γ, TNF-α and decreased anti-inflammatory IL-10), potentially slowing myelin destruction. Concurrently, progressive resistance training (typically at 60%-80% of maximum voluntary contraction) has been shown to improve muscle strength and reduce perceived fatigue in this population. However, data regarding the specific impacts of these exercise modalities on the immune system remain limited.
Objective:The aim of this randomized controlled trial is to investigate and compare the effects of AEROBIC AND STRENGTHENING (RESISTANCE) EXERCISES ON THE IMMUNE SYSTEM PARAMETERS (SPECIFICALLY CYTOKINE PROFILES) AND OVERALL FUNCTIONALITY IN INDIVIDUALS DIAGNOSED WITH MULTIPLE SCLEROSIS.
Detailed description
Multiple Sclerosis (MS) is recognized as a chronic immune-mediated, inflammatory, and neurodegenerative disorder of the central nervous system (CNS) characterized by axonal damage that disrupts neural conduction. The neurodegenerative nature of this neurological disease manifests through a wide spectrum of debilitating symptoms, including muscle weakness, fatigue, loss of balance, speech impairment, diplopia, and cognitive decline. These neurological signs and symptoms vary depending on the anatomical location of the lesions.
As an effective rehabilitation strategy for individuals with MS, exercise manages symptoms, restores function, optimizes quality of life, promotes wellness, and encourages participation in activities of daily living. Previous studies have demonstrated that aerobic activity is inversely associated with MS symptoms, exerting protective and potentially restorative effects. Furthermore, growing evidence suggests that exercise can be considered a disease-modifying therapy in MS. Although reductions in aerobic capacity and endurance are not primary clinical features of MS, they frequently develop as secondary manifestations. Therefore, strategies designed to enhance aerobic endurance and capacity, such as aerobic exercise, are highly valuable in MS management. Consequently, aerobic-based exercise interventions are frequently utilized in the therapeutic management of MS to improve aerobic endurance and capacity. Aerobik exercise is a modality designed to stress the cardiovascular system through continuous, rhythmic engagement of large muscle groups (e.g., jogging, walking, swimming, rowing, and cycle ergometry).
The anti-inflammatory effect of aerobic exercise may prevent systemic inflammatory progression. Exercise counteracts inflammation by reducing adipose tissue mass, which promotes the polarization of macrophages toward an anti-inflammatory state, thereby limiting cytokine production. Additionally, the downregulation of toll-like receptors associated with decreased inflammatory monocytes occurs. The inflammatory state is also modulated in response to exercise stimulation by increased levels of skeletal muscle-derived interleukin-6 (IL-6) and the prevention of sustained cytokine release associated with obesity. Cytokines, critical components of MS pathophysiology, are protein hormones that regulate communication between the innate and adaptive branches of the immune system. In healthy populations, a homeostatic balance exists among T-helper cytokines; however, this balance is altered in MS, reflecting increased proinflammatory cytokines (IL-1, IL-6) and decreased anti-inflammatory cytokines (IL-10). These aberrations can accelerate myelin destruction in the brain and spinal cord. Data regarding the effects of physical activity on the immune system in MS remain limited. Cytokines, the primary focus of exercise-based MS studies, encompass a spectrum of proinflammatory cytokines, including IL-1, IL-2, IL-6, IL-17, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α). Most of these cytokines are well-documented contributors to MS pathogenesis.
Recently, there has been a growing interest in resistance exercise training. Resistance training studies in individuals with MS have reported improvements in leg strength, reductions in perceived fatigue, and increases in muscle power. Resistance training protocols in this population have generally been of low-to-moderate intensity, typically utilizing progressive resistance exercise ranging from 60% to 80% of the maximum voluntary contraction.
The aim of this study is to conduct a randomized controlled trial to investigate the EFFECTS OF AEROBIC AND STRENGTHENING EXERCISES ON THE IMMUNE SYSTEM AND FUNCTIONALITY IN INDIVIDUALS DIAGNOSED WITH MULTIPLE SCLEROSIS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 3
- Model description
- This is a 3-arm, prospective, randomized controlled trial utilizing a parallel assignment design. Participants will be allocated into three distinct groups: MS Exercise Group (Experimental Arm): Individuals diagnosed with MS who will undergo a structured aerobic and strengthening exercise program. MS Control Group (Active/No Intervention Arm): Individuals diagnosed with MS who will maintain their routine medical care without participating in the exercise intervention. Healthy Control Group (Comparison Arm): Age- and gender-matched healthy individuals who will serve as a baseline reference for immune system parameters and functional capacity. The clinical, functional, and immunological outcomes (cytokine profiles) of all groups will be evaluated simultaneously at baseline and post-intervention to compare the treatment effects and baseline differences.
| Arm | Type | Receives |
|---|---|---|
| MS Exercise group | Experimental | Behavioral: Aerobic and Progressive Resistance Exercise ProgramParticipants diagnosed with Multiple Sclerosis who will perform a structured exercise program consisting of both aerobic training and progressive strengthening (resistance) exercises. |
| MS Control Group | Active comparator | Other: Standard Care (in control arm)Participants diagnosed with Multiple Sclerosis who will maintain their current routine medical care and daily life activities without participating in any structured exercise intervention during the study period. |
| healthy Control Group | Experimental | Behavioral: Aerobic and Progressive Resistance Exercise ProgramAge- and gender-matched healthy individuals who will perform the identical structured exercise program (consisting of aerobic and progressive strengthening exercises) as the MS Exercise Group. This arm will serve to compare the physiological, functional, and immunological (cytokine profiles) responses to exercise between healthy individuals and individuals with MS. |
Who may qualify
- Ages
- 19 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS). Aged between 19 and 45 years. Expanded Disability Status Scale (EDSS) score between 0.5 and 3.5. Not currently receiving steroid therapy (or having no recent corticosteroid treatment within the specified washout period).
Key exclusion criteria (9 listed)
- Having a high baseline level of physical activity.
- Experiencing an acute MS relapse or having a history of a relapse within the past 3 months.
- Presence of any orthopedic or bone pathology that would prevent participation in the exercise program.
- Concomitant diagnosis of any known neuromuscular or immunological disease other than MS.
- Initiating immunomodulatory therapy within the last 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aerobic and Progressive Resistance Exercise ProgramA structured, supervised exercise program consisting of both aerobic and progressive strengthening (resistance) exercises. Aerobic exercises will include continuous, rhythmic activities involving large muscle groups (e.g., cycle ergometry, walking). Progressive resistance training will target major muscle groups, typically utilizing an intensity ranging from 60% to 80% of the maximum voluntary contraction (MVC). The duration, frequency, and total weeks of the program will be identical for both exercise arms. | Behavioural | MS Exercise group, healthy Control Group |
| Standard Care (in control arm)Participants in this arm will maintain their current routine medical follow-ups and standard daily life activities. They will not participate in any structured or supervised physical exercise program during the study period. | Other | MS Control Group |
Primary outcome
CHANGE FROM BASELINE IN SERUM PROINFLAMMATORY CYTOKINE LEVELS
Time frame: Baseline and Post-intervention (e.g., Week 8)
Circulating serum levels of proinflammatory cytokines-specifically Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-17 (IL-17), Interferon-gamma (IFN-γ), and Tumor Necrosis Factor-alpha (TNF-α)-will be analyzed via Enzyme-Linked Immunosorbent Assay (ELISA) to evaluate the anti-inflammatory effect of the exercise program.
5 secondary outcomes
CHANGE FROM BASELINE IN FUNCTIONAL EXERCISE CAPACITY
Time frame: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN TIMED 25-FOOT WALK (T25FW)
Time frame: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN PERCEIVED FATIGUE IMPACT
Time frame: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN 9-HOLE PEG TEST (9HPT)
Time frame: Baseline and Post-intervention (e.g., Week 8)
CHANGE FROM BASELINE IN PACED AUDITORY SERIAL ADDITION TEST (PASAT-3)
Time frame: Baseline and Post-intervention (e.g., Week 8)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- ACUTE EFFECTS OF AEROBIC INTENSITIES ON THE CYTOKINE RESPONSE IN WOMEN WITH T MILD MULTIPLE SCLEROSISLink provided by the sponsor.
- INFLUENCE OF COMBINED FUNCTIONAL RESISTANCE AND ENDURANCE EXERCISE OVER 12 WEEKS ON MATRIX METALLOPROTEINASE-2 SERUM CONCENTRATION IN PERSONS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS - A COMMUNITY-BASED RANDOMIZED CONTROLLED TRIALLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data (IPD) collected during this trial will not be shared publicly to ensure patient confidentiality and comply with local data protection laws (Personal Data Protection Law / KVKK) and the institutional ethics committee approval. The ethical approval and informed consent forms signed by the participants do not cover the public repository sharing of raw individual data. However, the aggregated summary results and statistical findings will be made available through peer-reviewed publications.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
seda saka, Assoc. Prof. Dr. principal investigator
Haliç University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aerobic and Progressive Resistance Exercise Program in people with Multiple Sclerosis, run by Seda Saka at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact berna beren yıldırımoğlu, specialist physiotherapist (+905550823309, calppberna@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CHANGE FROM BASELINE IN SERUM PROINFLAMMATORY CYTOKINE LEVELS (time frame: Baseline and Post-intervention (e.g., Week 8)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.